Breaking News

Catalent, JOS Pharmaceuticals Enter Zydis Formulation Agreement

Catalent to undertake a feasibility study for the potential development of a CBD product for use as an anesthetic leveraging its ODT technology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent has signed an agreement with JOS Pharmaceuticals, a clinical stage biopharma company focused on anesthesiology, to undertake a feasibility study for the potential development of a licensed cannabidiol (CBD) product for use as an anesthetic premedication using Catalent’s Zydis orally disintegrating tablet (ODT) technology. Zydis technology creates a freeze-dried tablet that disperses almost instantly in the mouth without water. The feasibility study will be conducted at Catalent’s fac...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters